BioSpace News Archive

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received regulatory approval from Health Canada for a new oncology supportive care product.

Telesis Bio Inc. announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock.

Santhera Pharmaceuticals announces the publication of its Annual Report 2022 with fully audited results for the year ended December 31, 2022.

Redwood Pharma AB (publ) announces positive results from the company’s clinical study with RP501, a medical technology self-care product being developed for the treatment of dry eye.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older.

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) today announced the first subject has been dosed in a Phase 1 clinical trial evaluating BRII-297, a first-of-its-kind long-acting injectable (LAI), in development for the treatment of various anxiety and depressive disorders.

Spectros Medical Devices has pioneered a groundbreaking technology for monitoring the health of transplanted tissues in post-cancer and trauma reconstruction surgery, specifically in the highly specialized field of reconstructive micro-surgery.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced the pricing of an underwritten public offering of 22,900,768 shares of its common stock and 15,268 shares of its non-voting Series A-2 convertible preferred stock.

Antengene Corporation Limited announced that XPOVIO® in combination with bortezomib and dexamethasone is now listed on the PBS for the treatment of adult patients with R/R MM who have received at least one prior therapy.

At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, reinforces its commitment to progressing research of racial disparities in breast cancer through two poster presentations.